India's Dabur Pharma gets FDA nod for cancer drug


paclitaxel MUMBAI, Dec 7 (Reuters) - Indian drug maker Dabur Pharma Ltd. (DABR.BO) has received approval from the U.S. Food and Drug Administration for oncology drug paclitaxel injections, the regulatory agency's Web site showed.

Paclitaxel is the generic equivalent of Bristol-Myers Squibb Co.'s (BMY.N) Taxol, used in treating ovarian and breast cancer.

 © Reuters 2006.